Immunoblots of different proteins of the Akt/mTOR and MEK/ERK pathways were used to assess proper drug action, as already previously established [14], and to determine molecular differences in DLD-1 colon cancer cells grown in 2D and 3D culture upon treatment with selected dual and triple inhibitor combinations (Figure 1F and Figure S1C). The gene discussed is AKT1; the disease is malignant colon neoplasm.